U.S. markets closed

Cybin Inc. (CYBN)

NYSE American - NYSE American Delayed Price. Currency in USD
0.3569-0.0080 (-2.19%)
At close: 04:00PM EST
0.3600 +0.00 (+0.87%)
After hours: 07:54PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close0.3649
Bid0.3600 x 1100
Ask0.3720 x 1300
Day's Range0.3450 - 0.3800
52 Week Range0.3450 - 1.4300
Avg. Volume1,017,091
Market Cap67.905M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CYBN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cybin Inc.
    Daily Spotlight: Important Inflation News Out TodayThe Federal Reserve's favorite inflation indicator, the PCE Price Index, will be released by the BEA today. The PCE Index differs from the better-known Consumer Price Index in that its components are more variable and are quicker to reflect real-time pricing fluctuations. In the most-recent report (from September), PCE inflation was reported at 6.2% (the latest CPI report, from October, had inflation at 7.7%). At Argus, we forecast a rate of 5.9% for the October PCE Price Index. Core PCE, which removes volatile food and energy prices, was 5.1% in the last month. We expect the Core PCE to tick lower to 5.0% this month. Overall, inflation appears to have peaked during the summer and is starting to decline. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 5.2% rate year-over-year, down from 6.8% last month and from 8.7% four months ago. Drilling down to core inflation (which we obtain by averaging Core CPI, market-based PCE Ex-Food & Energy, the core GDP PCE Price Index, the five-year forward inflation expectation rate, and the 10-year TIPs Break-even Interest Rate), our reading is 4.1%. That's down slightly from our 4.3% reading last month. We note some movement among our components. Producer Prices appear to be cooling off, with substantial declines in PPI Intermediate Prices for Processed and Unprocessed Goods. The rate of wage increases also is slowing. Looking down the road, investors are expecting that the Federal Reserve's series of rate hikes ultimately will tame inflation, with the three-year forward expectation rate now down to 3.1% and the five-year forward expectation rate at 2.3%.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Business Wire

    Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

    TORONTO, November 15, 2022--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience ("SFN") taking place November 12-16, 2022, in San Diego, CA.

  • Business Wire

    Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

    TORONTO, November 14, 2022--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights.

  • Business Wire

    Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

    TORONTO, November 10, 2022--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce that its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine ("DMT") has completed dosing for four out of five participant cohorts and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The CYB004-E Phase 1 trial was acquired from Entheon Biom